Anti-tumor effect of a novel soluble recombinant human endostatin: administered as a single agent or in combination with chemotherapy agents in mouse tumor models.
Angiogenesis has become an attractive target in cancer treatment. Endostatin is one of the potent anti-angiogenesis agents. Its recombinant form expressed in the yeast system is currently under clinical trials. Endostatin suppresses tumor formation through the inhibition of blood vessel growth. It i...
Main Authors: | Zhihua Ren, Yanan Wang, Wenhong Jiang, Wei Dai, Yongping Jiang |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4168263?pdf=render |
Similar Items
-
Anti-tumor therapy with macroencapsulated endostatin producer cells
by: Balduino Keli N, et al.
Published: (2010-03-01) -
Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study
by: Jing-jing Ge, et al.
Published: (2020-01-01) -
Anti-tumor effect of local injectable hydrogel-loaded endostatin alone and in combination with radiotherapy for lung cancer
by: Na Wang, et al.
Published: (2021-01-01) -
Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models.
by: Fang Peng, et al.
Published: (2012-01-01) -
Rh-endostatin Concomitant with Chemotherapy Versus Single Agent Chemotherapy for Treating Soft Tissue and Bone Sarcomas: A Systematic Review and Meta-Analysis
by: Zhuo Ma, et al.
Published: (2018-10-01)